• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Primary Care
CMECNE

Changes in CDC Vaccination Guidance 2020

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss the changes to the CDC vaccine guidelines for 2020
2. Describe the new expanded CDC definition of chronic liver disease

Estimated time to complete activity: 0.5 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 12/01/2022 through 12/01/2024, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the test and evaluation. Upon registering and successfully completing the test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

SUMMARY:

Changes to the CDC Adult Immunization Schedule for 2020

Influenza

  • Routine annual influenza vaccination is recommended for
    • All individuals ≥6 months who do not have contraindications
    • One influenza vaccine product is not preferred over another
  • LAIV (influenza vaccine, live attenuated) is an option for adults through age 49 years with the following exceptions
    • Immunocompromising conditions, including HIV infection
    • Anatomical or functional asplenia
    • Pregnancy
    • Close contact with or are caregivers of severely immunocompromised persons in a protected environment
    • Have received influenza antiviral medications in the previous 48 hours
    • Cerebrospinal fluid leak
    • Cochlear implant

Note: “Those with a history of Guillain–Barré syndrome within 6 weeks of a previous dose of influenza vaccine generally should not be vaccinated, unless vaccination benefits outweigh risks for those at higher risk for severe complications from influenza.”

Hepatitis A

  • HepA vaccination is recommended for
    • All persons with HIV ≥1 year
  • Clotting factor disorders recommendation has been removed from the list
  • List of other higher risk population groups “has not changed significantly” and includes the following
    • Chronic liver disease
    • Travelers in countries with high or intermediate endemic hepatitis A
    • Close, personal contact with an international adoptee in the first 60 days after arrival from a country with high or intermediate endemic hepatitis A
    • Men who have sex with men
    • Persons who use injection or noninjection drugs
    • Persons experiencing homelessness
    • Persons who work with hepatitis A virus in a laboratory or nonhuman primates infected with the virus
  • Expanded definition of chronic liver disease: Now includes, but is not limited to persons with
    • Hepatitis B | Hepatitis C | Cirrhosis | Fatty liver disease | Alcoholic liver disease | Autoimmune hepatitis | ALT or AST level >2x upper limit of normal
  • Pregnancy: A 2-dose series HepA (or 3-dose series HepA-HepB) is recommended for pregnant women if they are at risk for Infection or severe outcome from infection during pregnancy
  • HepA vaccination is recommended for persons working in settings of exposure, including
    • Those working in health care settings for injection or noninjection drug users or group homes and nonresidential day care facilities for developmentally disabled persons)

Note: Any person who is not at risk for hepatitis A virus infection but wants protection against it may be vaccinated

Hepatitis B

  • The list of populations at risk for hepatitis B infection or severe hepatitis B disease has not changed
  • High risk list includes persons with
    • Hepatitis B | Hepatitis C | Cirrhosis | Fatty liver disease | Alcoholic liver disease | Autoimmune hepatitis | ALT or AST level >2x upper limit of normal
    • HIV infection
    • Sexual exposure risk such as
      • Sex partners of hepatitis B surface antigen [HBsAg]–positive person | Sexually active persons not in mutually monogamous relationships | Persons seeking evaluation or treatment of a sexually transmitted infection | Men who have sex with men
    • Current or recent injection drug use
    • Percutaneous or mucosal risk for exposure to blood such as
      • Household contacts of HBsAg-positive persons | Residents and staff of facilities for developmentally disabled persons | Health care and public safety personnel with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids | Hemodialysis |Peritoneal dialysis | Home dialysis | Predialysis patients
    • Diabetes mellitus
      • < 60 years
      • ≥60 years (at the discretion of the treating clinician)
    • Incarcerated persons
    • Persons traveling in countries with high or intermediate endemic hepatitis
  • Pregnancy – new ‘at risk group’
    • If at risk for infection or severe outcome from infection during pregnancy
    • Not recommended: HepB-Cpg (Heplisav-B) administration due to a lack of safety data

HPV

Catch-up HPV vaccination (not adequately vaccinated previously)

  • Through age 26
    • Catch-up HPV vaccination recommended for all adults, male and female
  • 27 through 45 years
    • Shared clinical decision-making is recommended

Public health benefit of HPV vaccinations for adults in this age range is minimal, yet some persons who are not adequately vaccinated might benefit. HPV vaccination does not need to be discussed with most adults older than 26 years of age, but clinicians can consider discussing HPV vaccination with persons who are most likely to benefit. HPV vaccines are not licensed for use in adults older than age 45 years.

Measles, mumps, and rubella (MMR)

  • Healthcare workers: Additional language added to address and clarify indications for health care workers
    • Born ≥1957 without evidence of immunity to measles, mumps, or rubella: A 2-dose series at least 4 weeks apart and at least 1 dose of MMR “should be administered” for rubella immunity
    • Born <1957 without evidence of immunity to measles, mumps, or rubella: “Consider” a 2-dose series at least 4 weeks apart for measles or mumps immunity and at least 1 dose MMR for rubella immunity

Meningococcal B

  • Persons ≥10 years with complement deficiency, complement inhibitor use, or asplenia or who are microbiologists
    • “Should receive” a MenB booster dose 1 year following completion of a MenB primary series, followed by MenB booster doses every 2–3 years thereafter, for as long as the increased risk remains
  • Persons ≥10 years determined by public health officials to be at increased risk during an outbreak
    • ACIP Recommends a one-time booster dose if it has been 1 year or more since completion of a MenB primary series
    • A booster dose interval of 6 months or more may be considered by public health officials depending on the specific outbreak, vaccination strategy, and projected duration of elevated risk

Pneumococcal Vaccination

  • PCV13 (pneumococcal 13-valent conjugate vaccine)
    • Offer based on shared clinical decision-making for adults ≥65 years and who have not previously received PCV13
    • Do not offer to those with an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant
  • PPSV23 (pneumococcal 23-valent polysaccharide vaccine
    • Recommended for all adults ≥65 years

Tetanus, Diphtheria, And Pertussis

  • ACIP recommends either Td or Tdap vaccine be used for the following clinical situations where only Td vaccine is currently recommended
    • Decennial booster
    • Tetanus prophylaxis in wound management
    • Catch-up immunization schedule, including in pregnant women

Varicella

  • Consider vaccination for persons with HIV without evidence of varicella immunity who have CD4 counts ≥200 cells/µL

Learn More – Primary Sources:  

Recommended Adult Immunization Schedule, United States, 2020

Take a post-test and get CME credits

TAKE THE POST TEST

Get Guideline Notifications Direct to Your Phone with ObGFirst™

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All Primary Care Posts
Next >

Related ObG Topics:

Vaccination in Pregnancy: CDC Recommendations and ACOG Update
New 2019 / 2020 CDC Flu Vaccine Guidance: Updated Recommendations
CDC Adult Vaccination Schedule

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site